Avencell
Next generation immunotherapies for hard-to-treat cancers.
- Headquarters
- Watertown, Massachusetts
- Employees
- 51–200
- Founded
- 2021
- Business Model
- B2B
- Website
- avencell.com
- Total Funding
- $152.0M
- Last Round
- $40.0M GrantJun 2025
About
AvenCell Therapeutics is a clinical-stage biopharma developing next-generation allogeneic and switchable CAR-T cell therapies for hard-to-treat cancers. Their proprietary platforms enable precise targeting, controllability, and safety, overcoming limitations of current immunotherapies. Backed by leading investors, they focus on advancing immunotherapies to improve patient outcomes globally.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account